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Abstract 
Purpose: In this study, we compared the dose impact of the heterogeneity 
caused by rectal gas using two methods of treatment planning for 
intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc 
therapy (VMAT). 
Materials and Methods: In addition to the structure set used for the 
standard treatment plan, we created a structure set for evaluation for each 
patient. The structure sets for evaluation that were created were transferred 
to the same iso-center as the respective treatment plans for IMRT and 
VMAT that were to become the standard. The values were then 
re-calculated.  
Results: During the standard prostatic IMRT and VMAT treatment 
planning, all the subjects met the dose restrictions in place at our hospital. 
Dose restrictions were fulfilled in the treatment plans for evaluation, 
excluding those with a clinical target volume (CTV) of V100% and planning 
target volume (PTV) of D95 when the rectum was excluded. However, in 
treatment plans for evaluation, IMRT was shown to have a higher 
concordance rate with standard treatment plans than VMAT. 
Conclusion: If rectal gas is present during either IMRT or VMAT, a dose 
decrease will occur in relation to CTV and PTV, suggesting that a plan does 
not eliminate adverse effects on organs at risk. 
Key words: Intensity-modulated radiotherapy, Volumetric-modulated arc 
therapy, Gas, Prostate cancer, Dose distribution  
1 Introduction 
According to the National Comprehensive Cancer Network (NCCN) 
guidelines for radiotherapy for prostate cancer, patient groups at low risk 
are those receiving 75.6–79.2 Gy and groups at medium to high risk are 
those receiving up to 81.0 Gy [1]. Reports suggest that increasing the dose to 
70–78 Gy reduces recurrence, particularly in moderate- to high-risk groups, 
suggesting the usefulness of a dose increase [2]. In the area surrounding the 
prostate, the organs at risk (OAR) are the rectum and bladder. For this 
reason, intensity-modulated radiotherapy (IMRT), which is capable of 
administering a uniform dose to the prostate while simultaneously 
minimizing radiation exposure of the surrounding OAR, is used at several 
institutions. Several reports of prostate IMRT have described results 
ranging from usefulness due to the physical dose distribution to superior 
clinical outcomes [3-5]. However, the dose gradient becomes steep at the 
boundary between the prostate and the surrounding OAR. Accordingly, 
insufficient precision when setting up the patient position has a major effect 
on the dose administered to both the prostate and the surrounding OAR. For 
this reason, image-guided radiotherapy (IGRT) is recommended in the 
NCCN guidelines when exposing patients to a prescribed dose of ≥78 Gy [1].  
IGRT uses 2- or 3-dimensional reference images to calculate and 
correct the change in patient position used in radiotherapy and then 
reproduces the site of irradiation as close as possible to the side determined 
during radiotherapy planning. It is based on either a two-dimensional 
collated image taken from two or more directions or a three-dimensional 
collated image. It is used as a verification technique for reproducing the 
exposure position that was determined in radiotherapy treatment planning 
as much as possible. When IGRT is used for position collation, there are two 
kinds: that for bone structure or that for target verification. There are 
reports of changes in the position of the prostate relative to the bone due to 
changes in bladder volume or rectal contents such as feces and gas, of which 
the effects from rectal gas are known to be the greatest [6-8]. Furthermore, 
as intrafraction organ motion is known to occur during the course of 
treatment, which changes the position of the prostate, it is desirable to 
shorten the treatment time by using volumetric-modulated arc therapy 
(VMAT) [9, 10]. However, in these reports, there was no detailed 
investigation of the effects of heterogeneity due to rectal gas that was absent 
during treatment planning.  
In this study, we evaluated the effects of rectal gas on dose 
distribution during prostatic IMRT and VMAT. Although VMAT is better 
than IMRT in terms of intrafraction organ motion, we compared the 
influence of rectal gas in both planning methods. 
 
2 Materials and Methods 
The subjects were 9 patients with prostate cancer treated with IMRT at 
our hospital. All patients were treated in the supine position. Patient 
characteristics are shown in Table 1. Only those who gave informed consent 
for the use of their data for research purposes were included in this study. 
The computed tomography (CT) machine used for treatment planning was a 
16-row multislice CT Optima CT580W (General Electric Medical Systems, 
Waukesha, WI, USA), with a field of view (FOV) of 500 mm, reconstructed 
slice thickness of 2.5 mm, and matrix size of 512 × 512. The treatment 
planning system (TPS) used for both IMRT and VMAT treatment planning 
was the Eclipse version 11.0.3 (Varian Medical Systems, Palo Alto, CA, 
USA). Contours were defined by a radiologist according to the contour 
depiction protocol at our hospital, as described later. The clinical target 
volume (CTV) is the volume of the prostate plus part of the seminal vesicles 
included in a 2 cm margin from the prostate (Fig. 1). The planning target 
volume (PTV) is an area established by setting a margin 6 mm posteriorly 
from the CTV and 8 mm in all other directions from the CTV. With respect to 
the rectal volume, the radiation therapy oncology group (RTOG) guidelines 
[11] state that it involves the area from the ischial tuberosity to the area 
between the descending colon and rectum or an area up to 15 cm in size. 
However, in this study, in order to minimize differences in the contour 
measurements between individuals, rectal volume was defined as the CTV 
plus 6 slices, which corresponds to 1.5 cm, in the craniocaudal direction from 
the CTV. 
 
2.1 Treatment planning 
The IMRT therapeutic images were obtained at 7 gantry angles of 0, 55, 
105, 155, 205, 255, and 305 degrees. At the gantry angles of 155 and 205 
degrees, we considered dose reduction through X-ray absorption in order to 
include the beam that passes through the treatment bed. For this reason, we 
corrected this by couch modeling. The dose prescribed during this study was 
76 Gy, which is a dose that covers 95% of the PTV (D95), with the overlapping 
rectum subtracted from the PTV area [12]. The linear accelerator used for 
treatment planning was NovalisTx (Varian Medical Systems, Palo Alto, CA) 
emitting 15MV-X. During the IMRT treatment planning, we applied an 
inverse planning technique using an optimization calculation algorithm, and 
created a fluence map in order to obtain the ideal dose distribution. 
Generally, a gradient method is used in an optimization calculation 
algorithm, and the level of achievement of the target dose established for 
each organ is calculated using a cost factor. We used the analytical 
anisotropic algorithm (AAA) as a dose calculation algorithm, and used a 
calculation grid size of 2.5 mm × 2.5 mm × 2.5 mm. In addition, there were 
two arcs for the gantry rotation angles used during VMAT planning: 181–
179 degrees in a clockwise (CW) direction and 179–181 in a counterclockwise 
(CCW) direction. The collimator angles used were 30 degrees and 330 
degrees. Couch modeling was used for correction as VMAT involves the 
passage of a beam through the treatment table. The prescribed dose was the 
same as that in IMRT. The beam dose restrictions used in this study are 
shown in Table 2. 
The volume of rectal gas in relation to the volume of the rectal contour 
used in treatment planning was 5% or less in all cases. In order to evaluate 
the effects exerted by rectal gas on the dose distribution, we created two 
types of structure set for the evaluation of each subject, in addition to 
creating a structure set using standard treatment planning. A summary of 
the two structure sets used for evaluation is as follows. A Hounsfield unit 
(HU) value of rectal gas is assigned to (1) the entire volume surrounded by 
the rectal contour, and (2) the area of overlap between the PTV and the 
rectum (overlap area). The mock values for the HU value of rectal gas were 
set as −950 based on the mean value of the gas in the rectum in the actual 
patients. Using the created structure sets that were used for the evaluation, 
the reference treatment plans for IMRT and VMAT were transferred to the 
same iso-center and recalculated. 
 
2.2 Plan evaluation 
Firstly, we evaluated the dose indicators in Table 3 for the prostatic IMRT 
and VMAT treatment plans. We used the paired t-test for statistical testing 
of the two groups in order to determine differences between IMRT and 
VMAT for all evaluation items. Using a technique similar to the above, we 
evaluated the difference between the treatment plan that was recalculated 
using the two structure sets created for the purpose of evaluation and the 
standard treatment plan. Furthermore, we used three-dimensional dose 
verification software (3DVH® version 2.2; SunNuclear, Melbourne, FL) and 
evaluated CTV, PTV, dose difference (DD) for bladder and rectal volume, 
distance to agreement (DTA), and gamma analysis (GA). The evaluation 
targets were DD (1%, 2%, 3%), DTA (1 mm, 2 mm, 3 mm), and GA (1%/1 mm, 
2%/2 mm, 3%/3 mm), and were always assessed at 10% of the threshold dose. 
The TPS measurement results depend on the results of the basic data 
through beam modeling. Thus, because less than 10% of the beam modeling 
is considered to be uncertain to a certain extent, in the present study, we 
selected 10%. The commercially available 3DVH software program can 
overcome some of the disadvantages of the planar gamma analysis concepts. 
With the aid of this software, the full 3D dose distribution can be 
reconstructed based on the measured data, and it can be compared to the 
TPS planning dose. In addition, a dose-volume histogram (DVH) for each 
target and each region of interest (ROI) can be drawn. In this study, we used 
two types of evaluation structure sets for comparison of the recalculated 
treatment plans, rather than using dose distribution that was reconstructed 
on the basis of measurement data. Similarly, we used the paired t-test for 
statistical testing of the two groups in order to determine differences 
between IMRT and VMAT for all evaluation items.  
 
3 Results 
The results of the comparison between the IMRT and VMAT therapeutic 
images for the 9 subjects are shown in Table 4. All subjects fulfilled the dose 
restrictions shown in Table 2. Except for the PTV minimum dose (p = 0.034) 
and V65Gy (p <0.01) in the bladder, no significant differences were observed. 
Table 5 shows the differences in the dose indicators between the standard 
treatment plan and the treatment plan where a mock HU value was 
assigned for gas in the entire rectum. There were no significant differences 
between the standard treatment plan for both IMRT and VMAT and the plan 
with assigned HU value for gas in the entire rectum in the maximum dose 
for CTV, rectal V70Gy, or bladder V40Gy and V65Gy. In addition, no significant 
differences were observed between the minimum PTV dose when using 
IMRT, and the mean PTV dose and rectal V60Gy when using VMAT.  
For both IMRT and VMAT, the doses for CTV and PTV were lower in the 
treatment plan where mock HU values were allocated for gas filling the 
entire rectum compared with those of the standard treatment plan, and the 
same decrease was observed in the high-dose regions of ≥75 Gy in the 
rectum. On the other hand, the values tended to be significantly higher in 
the moderate-dose areas of ≤ 60 Gy in the rectum. Non-significant changes in 
rectal V40Gy and V60Gy in IMRT, and PTV D95 and rectal V40 Gy in VMAT, were 
observed in the overlap gas group compared with the rectal gas group (Table 
5a, b). Excluding the CTV of V100% and the PTV D95 (with exclusion of the 
rectum), the dose distribution was fulfilled in all of the evaluation treatment 
plans. 
Table 6 shows the results of an analysis of the concordance of the dose 
distributions for the standard treatment plan and the two types of treatment 
plan using 3DVH. The results for 1% DD for CTV in treatment plans where 
mock HU values were allocated for gas filling only in the overlap region were 
91.16 ± 5.30% for IMRT and 88.12 ± 4.87% for VMAT, with a significant 
difference between the two (p = 0.026). For this reason, compared with 
VMAT, IMRT has a high concordance with the standard therapeutic plan. 
The results for 2% DD, similar to the results for 1% DD, showed significant 
differences (p = 0.022), but there was no significant difference for 3% DD (p = 
0.265). Similar to CTV, the PTV results at 1% DD and 2% DD showed that 
the concordance rate for VMAT was significantly lower. Furthermore, in 
terms of OAR, there were no significant differences in the results for IMRT 
and VMAT. With respect to DTA, there was no significant difference in any 
of the organs for DTA of 1 mm; there was no significant difference in any of 
the organs except the bladder for DTA of 2 mm; and there was a significantly 
higher concordance rate with IMRT for all volumes for DTA of 3 mm (with 
exclusion of the rectum). Finally, the results for GA showed that IMRT had a 
higher concordance with the standard treatment plans at CTV of 1%/1 mm 
and 2%/2 mm. For treatment plans where mock HU values were allocated for 
gas filling the entire rectum, in terms of the DD, there was a significantly 
higher concordance for IMRT when compared with the standard treatment 
plans for all CTV and PTV evaluation items. In the rectum and the bladder, 
in terms of DD, there were no significant differences observed in any of the 
evaluation items. During DTA, we excluded rectal 1 mm DTA and there was 
no significant difference in any of the results. There was a significant 
difference in the GA values for CTV and PTV at 1%/1 mm to 3%/3 mm, and 
IMRT showed higher concordance with the standard treatment plans. The 
rectal VMAT only showed significantly higher concordance at 1%/1 mm, but 
there were no results with significant differences in other evaluation items. 
Figure 2 shows the sagittal section 2% DD, 2 mm DTA, and 2%/2 mm GA for 
IMRT and VMAT treatment plans using the structure set for evaluation 
where mock HU values have been allocated for gas filling the entire rectum 
and for the treatment plans after substitution and recalculation. Figure 3 
also shows the axial dose distribution for the standard treatment plan and 
the recalculated treatment plan using the two types of structure set for 
evaluation.  
4 Discussion 
Increases in the dose of radiotherapy for prostate cancer are known to be 
useful for improving clinical outcomes [2]. Meanwhile, compared with 
normal three-dimensional conformal radiotherapy (3D-CRT), set up 
precision is more important when using irradiation methods that have a 
steep dose gradient, such as IMRT and VMAT. Zelefsky et al. investigated 
the outcome of treatment with or without IGRT performed at the same doses 
among patients with prostate cancer, and came to the conclusion that there 
was tumor suppression in high-risk cases and a reduction of delayed adverse 
drug reactions involving the bladder [13]. This suggests that, in IMRT, it is 
important to ensure the reproducibility of the dose distribution in both the 
prostate and the surrounding OAR during the period of radiotherapy 
treatment by performing IGRT. In a previous study focusing on the dose 
impact due to daily movement of the rectum, bladder, and prostate, after 
megavoltage CT imaging, the dose distribution in the treatment plan was 
substituted for recalculation [14]. Although implanted metallic markers 
were used (as references) to verify the target locations, the study revealed 
that discrepancies in the prostatic dose due to rectal contents such as feces or 
gas, or due to changes in the bladder volume, were approximately 10% at 
most. However, they did not show whether the dose distribution was affected 
by changes in the position of the prostate due to the presence of gas in the 
bowel, or by the heterogeneity caused by rectal gas that was not present in 
the rectum at the time of treatment planning. Therefore, in this study, we 
focused on rectal gas, which is said to be the key factor affecting the dose 
distribution in the prostate. However, we made the assumption that 
positional changes of the prostate do not occur, and then evaluated the 
effects of heterogeneity caused by rectal gas on the dose distribution during 
IMRT and VMAT. 
The dose restrictions shown in Table 2 in this study were taken as the 
standard, and we created the standard prostatic IMRT and VMAT treatment 
plans. From the results shown in Table 4, during standard prostatic IMRT 
and VMAT, we believe it is possible to formulate the same level of 
radiotherapy treatment plan. As shown in Table 5, a significant difference 
was observed in at least one dose index in all organs other than the bladder 
in the rectal gas group in both IMRT and VMAT. If there was gas present 
within the rectum, there was reduced dose scattering in the rectum 
compared with when there was no gas in the rectum; therefore, we believe 
that dose reduction occurred from the posterior wall of the CTV to the 
anterior wall of the rectum. For these reasons, significant differences were 
observed in the minimum dose for CTV, V100%, and mean dose in the 
standard treatment plan. The same can be said for the PTV and rectal V75Gy. 
In contrast, the values tended to be higher in moderate-dose regions of 60 Gy 
or less, compared with the standard treatment plan, suggesting that the dose 
that would have been absorbed in the rectum under normal circumstances 
was transmitted because of rectal gas. Accordingly, the dose was higher in 
the high-dose regions, and the opposite was shown in the moderate- to 
low-dose regions. The fact that no significant difference was noted for the 
bladder could be because it was separated and at some distance from the 
rectal gas and therefore exerted no effect. In the overlap group, differences in 
the dose distribution for the standard IMRT and VMAT treatment plans 
were small when compared with the rectal gas group, but still significant 
differences were observed in some dose indicators such as the minimum and 
mean CTV doses (p<0.01). The fact that there was reduced dose scattering 
when the values for gas in the overlap region were allocated, similar to what 
was discussed previously, shows that there is an effect on the 
high-dose-region dose indicators ≥ 75 Gy in the rectum. Meanwhile, we 
compared the structure set allocated values for when rectal gas was present 
in the overlap region only with the structure set where mock values were 
allocated for gas present throughout the rectum and found that the effects 
were small in the dose regions in the rectum that received ≤70 Gy. On the 
basis of the concordance results of the standard IMRT and VMAT treatment 
plans and after substituting the two types of structure set in the standard 
treatment plan and recalculating, we then discussed performing dose 
distribution substitution and recalculation in the structure set where there 
was allocation of values for gas throughout the rectum during IMRT and 
VMAT. On the basis of the DD and DTA results, if we focus on the rectum, 
the concordance rate for the DD for both IMRT and VMAT is low compared 
with that for DTA. However, DD conversely shows higher concordance than 
DTA for CTV and PTV. On this basis, this would cause differences in the 
dose impact on various organs and the characteristics of the dose 
distribution. Only the organs in the CTV and PTV should be irradiated, but 
not the rectum as it is an OAR; the advantage of IMRT and VMAT is that 
these are the only methods capable of providing this exposure. Because the 
dose distribution has these characteristics, the effects of the CTV and the 
PTV on the DD were low. With regard to the rectum, we believe that the DD 
was extremely low because there is a dose distribution that involves dose 
changes in a fixed range extending from the anterior to the posterior rectal 
wall. In terms of the DTA, the most important evaluation is whether the 
compared dose provides the same dose within the shortest distance; 
therefore, we did not observe an extreme decrease in concordance as with DD. 
On this basis, we believe that the GA in this evaluation is appropriate when 
the concordance rate uses either the DD or the DTA only. There was a 
significant difference in the GA values for CTV and PTV at 1%/1 mm to 3%/3 
mm (p<0.01), and IMRT showed a higher concordance rate with standard 
treatment plans. This means that the PTV was irradiated with a greater 
dose in the direction of the rectum in the VMAT treatment plans than in the 
IMRT treatment plans. Accordingly, in the case of VMAT, there is scope for 
investigating a radiation method such as partial restriction of the beam 
radiation angle from the direction of the rectum. However, because the AAA 
dose calculation algorithm used in this study does not accurately calculate 
changes in density in highly heterogeneous regions, it is possible that the 
value for the rectum is being overestimated and that for the posterior wall of 
the CTV is being underestimated [14]. In the future, we plan to use Acuros 
XB or XVMC, which are dose calculation algorithms that are equivalent to 
Monte Carlo simulation. 
In this study, even when the entire rectal volume was filled with gas, it 
was possible to meet the dose restrictions for OAR at our hospital. Thus, 
during exposure prior to position verification, even when there is gas present 
in the rectum, if there are no changes in the position of the prostate, it is 
possible to continue irradiation without causing adverse events in OAR even 
though dose reduction occurs in CTV and OTV. Meanwhile, at many 
institutions, the concordance rate at 3%/3 mm is used to investigate the dose 
distribution for IMRT and VMAT, and the GA results in this study suggest 
that, if the criteria are fulfilled, the therapy can be performed safely. The 
minimum concordance rate was 95.4% during IMRT and 93.1% during 
VMAT, and in either case, there was concordance in the CTV, but these 
results suggest that it is safe to continue treatment. 
Next, in the case where there was substitution and recalculation for rectal 
gas only in the overlap region, compared with when values were allocated for 
gas filling the entire rectum, the percentage of gas was obviously smaller, 
but when the 1% and 2% DD in the CTV and PTV were evaluated and 
compared with the VMAT, the IMRT had significantly better concordance 
with the standard treatment plans. In the same way as for conventional 
treatment plans, when trying to support exposure to the dose distribution, 
we believe that the rectal gas content below the overlap area must be 
minimized. However, when gas is in the overlap region, on the basis of the 
results of GA, even if there is concordance with 2%/2 mm, the minimum 
concordance is 98.4% for IMRT and 96.1% for VMAT. As previously 
mentioned, we believe that this concordance rate showed that clinical 
irradiation can be performed without a problem. In addition, during the 
present study, although all subjects had rectal gas content that was 5% or 
less of the rectal volume, the results showed that it is possible to perform 
irradiation even if gas is present in the overlap region as long as there is no 
change in prostate position. 
 
5. Conclusions 
 During this study, in order to evaluate the effects on dose distribution 
related to the homogeneity created by gas that was not present in the rectum 
during the treatment planning for prostatic IMRT and VMAT, we assumed 
no change in the position of the prostate. The results suggested that, 
compared with VMAT, even when there is gas present in the rectum during 
IMRT, the effects on dose distribution are low compared with when there is 
no gas in the rectum. However, even though a dose reduction occurred in the 
CTV and PTV when rectal gas was present during both IMRT and VMAT, 
dose restrictions for the OAR at our hospital were met. In addition, a 
concordance rate of 93.1% was obtained in relation to CTV and PTV for a GA 
of 3%/3 mm, suggesting that treatment can be concluded successfully if a 
change in the position of the prostate does not occur.  
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Figure Legends 
Fig. 1 Delineation of the clinical target volume (CTV). CTV includes the 
seminal vesicles within 2 cm of the prostate. 
 
Fig. 2 The sagittal section 2% DD, 2 mm DTA, and 2%/2 mm GA for IMRT 
and VMAT treatment plans using the structure set for evaluation where 
mock HU values have been allocated for gas filling the entire rectum and 
for the treatment plans after substitution and recalculation. In the red 
area, we compared areas that did not match the permitted value for each 
evaluation item to standard treatment planning, showing that the dose was 
higher. In the blue area, we compared areas that did not match the 
permitted value for each evaluation item to standard treatment planning, 
showing that the dose was lower. 
(a) IMRT 2% DD, (b) VMAT 2% DD, (c) IMRT 2 mm DTA, (d) VMAT 2 mm 
DTA, (e) IMRT 2%/2 mm GA, (f) VMAT 2%/2 mm GA 
DD: dose difference 
DTA: distance to agreement 
GA: gamma analysis 
 
Fig. 3 Dose distribution in the sagittal plane for the standard treatment plan 
and the treatment plan recalculated using the two types of structure set for 
evaluation 
(a) The dose distribution for the standard prostatic intensity-modulated 
radiation therapy (IMRT) treatment plan. 
(b) The dose distribution for IMRT for the planning target volume (PTV) 
after substitution and recalculation using the structure set for analysis 
when the HU value was allocated for gas filling the overlap region. 
(c) The dose distribution for IMRT after substitution and recalculation using 
the structure set for analysis when the HU value was allocated for gas 
filling the entire rectum. 
(d) The dose distribution for the standard prostatic volumetric-modulated 
radiation therapy (VMAT) treatment plan. 
(e) The dose distribution for VMAT treatment planning for the PTV after 
substitution and recalculation using the structure set for analysis when the 
HU value was allocated for gas filling the overlap region. 
(f) The dose distribution for VMAT treatment planning after substitution 
and recalculation using the structure set for analysis when the HU value 
was allocated for gas filling the entire rectum. 
 
Table 1 Patients characteristics. 
PSA: preretirement spouse annuity 
Table 2 Dose-volume constraints used in the planning. 
Table 3 Dose evaluation used in the planning. 
Table 4 Dosimetric comparison of organs at risk and target dose of IMRT and 
VMAT plans. 
Table 5 Differences in the dose indicators when using the standard 
treatment plan and the two types of treatment plan for evaluation. 
(a) IMRT, (b) VMAT 
Overlap gas: The treatment plan using the structure set that was allocated 
an HU value for mock gas in the overlap area of the rectum. 
Rectum gas: The treatment plan using the structure set that was allocated 
an HU value for mock gas in the entire rectum. 
Table 6 Results of concordance of the dose distributions for the standard 
treatment plan and the two types of treatment plan under evaluation. 
(a) The DD concordance results when using the standard treatment plan and 
the structure set using an HU value for mock gas filling the overlap 
region. 
(b) The DTA concordance results when using the standard treatment plan 
and the structure set using an HU value for mock gas filling the overlap 
region. 
(c) The GA concordance results when using the standard treatment plan and 
the structure set using an HU value for mock gas filling the overlap 
region. 
(d) The DD concordance results when using the standard treatment plan and 
the structure set using an HU value for mock gas filling the entire 
rectum. 
(e) The DTA concordance results when using the standard treatment plan 
and the structure set using an HU value for mock gas filling the entire 
rectum. 
(f) The GA concordance results when using the standard treatment plan and 
the structure set using an HU value for mock gas filling the entire 
rectum. 
DD: dose difference 
DTA: distance to agreement 
GA: gamma analysis 
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Figures
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Fig 1  Delineation of the clinical target volume (CTV). 
CTV includes the seminal vesicles within 2 cm of the prostate.
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